Physician profile
Sunil Chandra
NPI 1417060666
$3,863.20
in general payments reported to CMS, 2019-2025
37 companies · $161 in 2025
The $161 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $764 · 2021: $924 · 2022: $613 · 2023: $789 · 2024: $345 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,281 · Entertainment: $13.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,281.49 |
| Entertainment | $13.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $444.88 | 2020-2022 | |
| Glaxosmithkline, LLC. | $437.56 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $370.32 | 2019-2025 | Farxiga, Lokelma, Breztri |
| Novartis Pharmaceuticals Corporation | $345.90 | 2019-2024 | |
| Astellas Pharma US INC | $325.19 | 2019-2023 | Veozah |
| Lilly USA, LLC | $257.26 | 2020-2024 | Mounjaro, Jardiance, Lyumjev |
| Novo Nordisk INC | $223.30 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $176.59 | 2021-2025 | Qulipta, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $140.05 | 2020-2021 | |
| Pfizer INC. | $122.06 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.26 | 2021-2024 | Ofev |
| Abbott Laboratories | $94.09 | 2021-2024 | Freestyle Libre 3 |
| Amgen INC. | $88.85 | 2020-2025 | Krystexxa, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.08 | 2020-2024 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $84.24 | 2022-2023 | Gvoke Hypopen |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $52.21 | 2022-2023 | Linzess |
| Dexcom, INC. | $51.69 | 2021-2024 | Dexcom G6 Transmitter |
| Electromed, INC. | $48.67 | 2021-2022 | |
| Shield Therapeutics INC | $48.40 | 2022-2023 | Accrufer |
| Allergan, INC. | $35.82 | 2019 | |
| Amarin Pharma, INC. | $33.23 | 2019-2021 | |
| Global Blood Therapeutics, INC. | $30.22 | 2020 | |
| Genzyme Corporation | $29.84 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.22 | 2024 | |
| Hikma Pharmaceuticals USA | $18.44 | 2019 | |
| Csl Behring | $17.28 | 2019 | |
| Evoke Pharma, INC. | $17.10 | 2024 | |
| Mylan Specialty L.P. | $16.58 | 2021 | |
| Esperion Therapeutics, INC. | $16.20 | 2021 | |
| Corcept Therapeutics | $14.78 | 2025 | Korlym |
| Lundbeck LLC | $14.74 | 2025 | Rexulti |
| Horizon Therapeutics Plc | $14.31 | 2021 | |
| Exact Sciences Corporation | $13.81 | 2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $13.70 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.60 | 2022 | |
| Optos, INC. | $13.52 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Jazz Pharmaceuticals INC. | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.